文献速递其他结缔组织病血管炎

托珠单抗治疗白塞病的系统文献综述

Effectiveness of tocilizumab in Behcet's disease: A systematic literature review.
PubMed 文献 · Semin Arthritis Rheum · 2020-06-05

该系统文献综述纳入47例难治性白塞病患者,评估托珠单抗的疗效。结果显示托珠单抗对眼、神经、血管受累及继发性淀粉样变有效,但对口腔/生殖器溃疡、皮肤和关节病变效果不佳,甚至可能加重溃疡。

要点

  • 托珠单抗对难治性眼、神经、血管白塞病及继发性淀粉样变有效。
  • 托珠单抗不推荐用于黏膜皮肤和关节受累的白塞病患者。
  • 部分患者口腔/生殖器溃疡和皮肤病变在托珠单抗治疗后加重。

核心结论

  • 托珠单抗对难治性眼、神经、血管白塞病及继发性淀粉样变有效,可作为替代治疗。
  • 托珠单抗不推荐用于黏膜皮肤和关节受累的白塞病患者。

研究设计与样本

  • 系统文献综述,检索从建库至2020年4月10日报告托珠单抗治疗白塞病的文献。
  • 共纳入47例接受托珠单抗治疗的白塞病患者,平均给药年龄36.9岁,55%为女性,平均病程99.5±61.4个月,均为对既往传统和生物制剂难治。

主要发现

  • 托珠单抗改善几乎所有眼(24/25)、神经(6/6)、血管(7/7)受累及继发性淀粉样变(2/2)患者。
  • 托珠单抗减少几乎所有眼(19/21)、神经(6/6)、血管(7/7)受累患者的糖皮质激素剂量。
  • 眼受累21例中11例、神经受累6例中3例达到无糖皮质激素缓解。
  • 口腔/生殖器溃疡21例中仅8例、皮肤受累14例中仅6例、关节受累11例中仅4例、胃肠道受累4例中仅3例临床改善。
  • 口腔/生殖器溃疡21例中6例、皮肤病变15例中2例在托珠单抗治疗后加重;未报告新的安全性信号。

关键数值与推荐

  • 眼受累改善24/25,神经受累改善6/6,血管受累改善7/7,继发性淀粉样变改善2/2。
  • 糖皮质激素减量:眼受累19/21,神经受累6/6,血管受累7/7。
  • 无糖皮质激素缓解:眼受累11/21,神经受累3/6。
  • 黏膜皮肤和关节受累改善率低:口腔/生殖器溃疡8/21,皮肤6/14,关节4/11,胃肠道3/4。
  • 加重:口腔/生殖器溃疡6/21,皮肤病变2/15。

临床怎么用

  • 对于难治性眼、神经、血管白塞病及继发性淀粉样变,托珠单抗可作为替代治疗选择。
  • 不推荐托珠单抗用于以黏膜皮肤或关节受累为主的白塞病患者。
  • 使用托珠单抗期间需监测口腔/生殖器溃疡及皮肤病变是否加重。

局限性

  • 系统文献综述基于病例报告和小样本研究,证据级别有限。
  • 样本量小(47例),各器官受累亚组例数更少。
  • 缺乏对照设计和统一疗效评估标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Behcet's disease is a systemic disorder with ocular, mucocutaneous, and vascular involvement. The efficacy of tumor necrosis factor inhibition has been established; however, that of interluekin-6 inhibition is unclear. We investigated the effectiveness of tocilizumab, an anti-interleukin-6 receptor antibody, in patients with Behcet's disease. METHODS: We performed a systematic literature review from the inception dates until April 10, 2020 for articles reporting tocilizumab administration for the treatment of Behcet's disease. RESULTS: We identified 47 patients with Behcet's disease treated with tocilizumab. The mean age at tocilizumab administration was 36.9 years, and 55% of the patients were female. The mean disease duration was 99.5 ± 61.4 months, and all patients had refractory disease in response to prior conventional and biologic agents. Clinical response to tocilizumab varied based on the target organs. Tocilizumab improved almost all patients with ocular (24/25), neurological (6/6), and vascular (7/7) involvement, as well as secondary amyloidosis (2/2). Tocilizumab was also effective in reducing glucocorticoid dose in almost all patients with ocular (19/21), neurological (6/6), and vascular (7/7) involvement. Further, glucocorticoid-free remission was achieved in 11 of 21 patients with ocular involvement and in 3 of 6 with neurological involvement. However, tocilizumab was not very effective for other manifestations, showing clinical improvement in only 8 of 21 patients with oral or genital ulcers, 6 of 14 with skin involvement, 4 of 11 with articular involvement and 3 of 4 with gastrointestinal involvement. Of note, tocilizumab even worsened oral or genital ulcers in 6 of 21 patients and skin lesion in 2 of 15 patients. No new safety signal was reported. CONCLUSION: Tocilizumab was effective and can serve as an alternative treatment for refractory ocular-, neuro-, and vasculo-Behcet's disease, as well as secondary amyloidosis, but was not recommended for patients with mucocutaneous and articular involvement.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Akiyama M, Kaneko Y, Takeuchi T, et al. Effectiveness of tocilizumab in Behcet's disease: A systematic literature review. Semin Arthritis Rheum. 2020. PMID: 32544751. doi:10.1016/j.semarthrit.2020.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。